Alain Mayindu Ngoma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alain Mayindu Ngoma has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Hitoshi Ohto
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
7 shared publications- Kenneth E. Nollet
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan; Radiation Medical Science Center for the Fukushima Health Management Survey, Fukushima Medical University, Fukushima, Japan
7 shared publications Kenneth E. Nollet
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
6 shared publications- Hitoshi Ohto
Radiation Medical Science Center for the Fukushima Health Management Survey, Fukushima Medical University, Fukushima 960-1295, Japan
5 shared publications Seiji Yasumura
Department of Public Health, Fukushima, Japan
4 shared publications- Aya Goto
Fukushima Medical University
3 shared publications
Latest Publications
- 2 March 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (6) , 689-699
Acute transfusion reactions in sub‐Saharan Africa: A systematic review and meta‐analysis
Background and Objectives: Sub‐Saharan Africa (SSA) faces significant challenges in implementing effective haemovigilance systems, thereby increasing the risk of adverse events following transfusion. This systematic review and meta‐analysis assessed the frequency, clinical patterns and determinants of acute transfusion reactions (ATRs) in the region, in order to inform evidence‐based prevention strategies. Materials and Methods: The review followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, and the studies were a priori stratified by design. Pooled proportions were calculated using a random‐effects meta‐analysis. Results: Twenty‐six studies conducted in 13 countries and published up to 30 November 2024 were included; 15 were retrospective and 11 were prospective. When calculated per patient, the pooled ATR rate was 64 per 1000 patients in retrospective studies and 112 per 1000 patients in prospective studies. When estimated per unit transfused, the corresponding rates were 23 per 1000 units and 136 per 1000 units, respectively. The most frequently reported manifestations were consistent with febrile non‐haemolytic reactions (41.8%) and allergic reactions (24.9%). Potentially life‐threatening reactions occurred in 14%, and 0.94% resulted in death. Whole blood transfusion, multiple transfused units and previous transfusion exposure were identified as factors associated with ATR occurrence. Conclusion: ATRs are common in SSA and are strongly associated with the use of whole blood. The broader implementation of blood component therapy could substantially reduce their burden. Central to ATR prevention in the region are strengthening pre‐transfusion evaluation and testing, expanding leukoreduction, establishing robust in‐hospital haemovigilance systems and promoting appropriate blood use.
- 2 March 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (6) , 689-699
Acute transfusion reactions in sub‐Saharan Africa: A systematic review and meta‐analysis
Background and Objectives: Sub‐Saharan Africa (SSA) faces significant challenges in implementing effective haemovigilance systems, thereby increasing the risk of adverse events following transfusion. This systematic review and meta‐analysis assessed the frequency, clinical patterns and determinants of acute transfusion reactions (ATRs) in the region, in order to inform evidence‐based prevention strategies. Materials and Methods: The review followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, and the studies were a priori stratified by design. Pooled proportions were calculated using a random‐effects meta‐analysis. Results: Twenty‐six studies conducted in 13 countries and published up to 30 November 2024 were included; 15 were retrospective and 11 were prospective. When calculated per patient, the pooled ATR rate was 64 per 1000 patients in retrospective studies and 112 per 1000 patients in prospective studies. When estimated per unit transfused, the corresponding rates were 23 per 1000 units and 136 per 1000 units, respectively. The most frequently reported manifestations were consistent with febrile non‐haemolytic reactions (41.8%) and allergic reactions (24.9%). Potentially life‐threatening reactions occurred in 14%, and 0.94% resulted in death. Whole blood transfusion, multiple transfused units and previous transfusion exposure were identified as factors associated with ATR occurrence. Conclusion: ATRs are common in SSA and are strongly associated with the use of whole blood. The broader implementation of blood component therapy could substantially reduce their burden. Central to ATR prevention in the region are strengthening pre‐transfusion evaluation and testing, expanding leukoreduction, establishing robust in‐hospital haemovigilance systems and promoting appropriate blood use.
- 11 February 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (2) , 104086
The 2024 international survey of platelet products and practice
- 11 February 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (2) , 104086
The 2024 international survey of platelet products and practice
- 2 October 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 101 (4) , 908-915
Prevalence and Molecular Epidemiology of Human T-Lymphotropic Virus Type 1 among Women Attending Antenatal Clinics in Sub-Saharan Africa: A Systematic Review and Meta-Analysis
Human T-cell lymphotropic virus type 1 (HTLV-1) imposes a substantial disease burden in sub-Saharan Africa (SSA), which is arguably the world’s largest endemic area for HTLV-1. Evidence that mother-to-child transmission persists as a major mode of transmission in SSA prompted us to estimate the pooled prevalence of HTLV-1 among pregnant women throughout the region. We systematically reviewed databases including EMBASE, MEDLINE, Web of Science, and the Cochrane Database of Systemic Reviews from their inception to November 2018. We selected studies with data on HTLV-1 prevalence among pregnant women in SSA. A random effect meta-analysis was conducted on all eligible data and heterogeneity was assessed through subgroup analyses. A total of 18 studies, covering 14,079 pregnant women, were selected. The evidence base was high to moderate in quality. The pooled prevalence, per 100 women, of the 18 studies that screened HTLV-1 was 1.67 (95% CI: 1.00–2.50), a figure that masks regional variations. In Western, Central, Southern, and Eastern Africa, the numbers were 2.34 (1.68–3.09), 2.00 (0.75–3.79), 0.30 (0.10–0.57), and 0.00 (0.00–0.21), respectively. The prevalence of HTLV-1 infection among pregnant women in SSA, especially in Western and Central Africa, strengthens the case for action to implement routine screening of pregnant women for HTLV-1. Rigorous studies using confirmatory testing and molecular analysis would characterize more accurately the prevalence of this infection, consolidate the evidence base, and further guide beneficial interventions.
- 2 October 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 101 (4) , 908-915
Prevalence and Molecular Epidemiology of Human T-Lymphotropic Virus Type 1 among Women Attending Antenatal Clinics in Sub-Saharan Africa: A Systematic Review and Meta-Analysis
Human T-cell lymphotropic virus type 1 (HTLV-1) imposes a substantial disease burden in sub-Saharan Africa (SSA), which is arguably the world’s largest endemic area for HTLV-1. Evidence that mother-to-child transmission persists as a major mode of transmission in SSA prompted us to estimate the pooled prevalence of HTLV-1 among pregnant women throughout the region. We systematically reviewed databases including EMBASE, MEDLINE, Web of Science, and the Cochrane Database of Systemic Reviews from their inception to November 2018. We selected studies with data on HTLV-1 prevalence among pregnant women in SSA. A random effect meta-analysis was conducted on all eligible data and heterogeneity was assessed through subgroup analyses. A total of 18 studies, covering 14,079 pregnant women, were selected. The evidence base was high to moderate in quality. The pooled prevalence, per 100 women, of the 18 studies that screened HTLV-1 was 1.67 (95% CI: 1.00–2.50), a figure that masks regional variations. In Western, Central, Southern, and Eastern Africa, the numbers were 2.34 (1.68–3.09), 2.00 (0.75–3.79), 0.30 (0.10–0.57), and 0.00 (0.00–0.21), respectively. The prevalence of HTLV-1 infection among pregnant women in SSA, especially in Western and Central Africa, strengthens the case for action to implement routine screening of pregnant women for HTLV-1. Rigorous studies using confirmatory testing and molecular analysis would characterize more accurately the prevalence of this infection, consolidate the evidence base, and further guide beneficial interventions.
- Open Access
- 29 August 2019
- Published by Wiley in Tropical Medicine & International Health
- Vol. 24 (11) , 1277-1290
Population‐based prevalence of human T‐lymphotropic virus type 1 in sub‐Saharan Africa: a systematic review and meta‐analysis
Background: Human T‐cell lymphotropic virus type 1 (HTLV‐1), the causative agent of adult T‐cell leukaemia/lymphoma (ATL) and HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), is endemic in sub‐Saharan Africa (SSA) and poses a high morbidity and mortality risk. Its prevalence in the general population is poorly understood. The potential for prevention motivated us to do a systematic review and meta‐analysis of population‐based studies to estimate the prevalence of HTLV‐1 in SSA.Methods: A comprehensive, no‐limit search was conducted in EMBASE, PubMed, Web of Science and the Cochrane Library from their inception dates to March 2019. Population‐based studies presenting data on HTLV‐1 in sub‐Saharan Africa were included. Pooled prevalence was estimated using a random‐effects meta‐analysis.Results: A total of 21 studies were included, representing 42 297 participants. The pooled HTLV‐1 seroprevalence was 3.19% (95% CI 2.36–4.12%) with variations across year of study. Prevalence of HTLV‐1 positively correlated with year of study (β = 0.0036, P = 0.007). Participants from Central, Western and Southern Africa had a seroprevalence of 4.16% (95% CI 2.43–6.31%), 2.66% (95% CI 1.80–3.68%) and 1.56% (95% CI 0.48–3.15%), respectively.Conclusions: Our findings suggest that HTLV‐1 infection is a public health concern in SSA and highlight the need to implement effective preventive programmes and interventions aimed at reducing the burden of this common yet neglected infection.
- 29 August 2019
- Published by Wiley in Tropical Medicine & International Health
- Vol. 24 (11) , 1277-1290
Open AccessPopulation‐based prevalence of human T‐lymphotropic virus type 1 in sub‐Saharan Africa: a systematic review and meta‐analysis
Background: Human T‐cell lymphotropic virus type 1 (HTLV‐1), the causative agent of adult T‐cell leukaemia/lymphoma (ATL) and HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), is endemic in sub‐Saharan Africa (SSA) and poses a high morbidity and mortality risk. Its prevalence in the general population is poorly understood. The potential for prevention motivated us to do a systematic review and meta‐analysis of population‐based studies to estimate the prevalence of HTLV‐1 in SSA.Methods: A comprehensive, no‐limit search was conducted in EMBASE, PubMed, Web of Science and the Cochrane Library from their inception dates to March 2019. Population‐based studies presenting data on HTLV‐1 in sub‐Saharan Africa were included. Pooled prevalence was estimated using a random‐effects meta‐analysis.Results: A total of 21 studies were included, representing 42 297 participants. The pooled HTLV‐1 seroprevalence was 3.19% (95% CI 2.36–4.12%) with variations across year of study. Prevalence of HTLV‐1 positively correlated with year of study (β = 0.0036, P = 0.007). Participants from Central, Western and Southern Africa had a seroprevalence of 4.16% (95% CI 2.43–6.31%), 2.66% (95% CI 1.80–3.68%) and 1.56% (95% CI 0.48–3.15%), respectively.Conclusions: Our findings suggest that HTLV‐1 infection is a public health concern in SSA and highlight the need to implement effective preventive programmes and interventions aimed at reducing the burden of this common yet neglected infection.
- 1 July 2019
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 33 (3) , 162-169
Red Blood Cell Alloimmunization in Transfused Patients With Sickle Cell Disease in Sub-Saharan Africa; a Systematic Review and Meta-Analysis
- 1 July 2019
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 33 (3) , 162-169
Red Blood Cell Alloimmunization in Transfused Patients With Sickle Cell Disease in Sub-Saharan Africa; a Systematic Review and Meta-Analysis
- 11 April 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (5) , 413-425
Seroprevalence of human T‐lymphotropic virus (HTLV) in blood donors in sub‐Saharan Africa: a systematic review and meta‐analysis
Background and objective: Human T‐cell lymphotropic viruses (HTLV) 1 and 2 are endemic in sub‐Saharan Africa (SSA), transfusion‐transmissible and causally linked to various severe diseases. However, even in SSA countries with moderate to high endemicity, routine blood donor screening for HTLV is rarely, if ever, performed. Information on seroprevalence is limited. The aim of this review is to establish the prevalence of HTLV‐1 and HTLV‐1/2 among blood donors in sub‐Saharan Africa.Materials and Methods: We systematically reviewed databases including EMBASE, MEDLINE and the Cochrane database library from their inception to June 2018. Studies presenting data on HTLV prevalence among blood donors in sub‐Saharan Africa were included. A random‐effect meta‐analysis was conducted on all eligible studies.Results: A total of 25 studies were included, representing 74 119 blood donors, of whom over 80% (61 002) were only tested for HTLV‐1. The evidence base was high and moderate in quality. The pooled prevalence of the 17 studies that screened only for HTLV‐1 and the nine studies that screened for HTLV‐1/2 was 0·68 (95% CI: 0·29–1·60) and 1·11 (95% CI: 0·47–2·59) per 100 blood donors, respectively.Conclusion: The prevalence of HTLV‐1 infection among blood donors is relatively low. The current review is intended to inform debates and decisions about best practices to prevent transfusion‐transmitted HTLV in sub‐Saharan Africa. Further work is required to determine the risk of infections by transfusion and the cost‐effectiveness of any new measures such as routine screening.
- 11 April 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (5) , 413-425
Seroprevalence of human T‐lymphotropic virus (HTLV) in blood donors in sub‐Saharan Africa: a systematic review and meta‐analysis
Background and objective: Human T‐cell lymphotropic viruses (HTLV) 1 and 2 are endemic in sub‐Saharan Africa (SSA), transfusion‐transmissible and causally linked to various severe diseases. However, even in SSA countries with moderate to high endemicity, routine blood donor screening for HTLV is rarely, if ever, performed. Information on seroprevalence is limited. The aim of this review is to establish the prevalence of HTLV‐1 and HTLV‐1/2 among blood donors in sub‐Saharan Africa.Materials and Methods: We systematically reviewed databases including EMBASE, MEDLINE and the Cochrane database library from their inception to June 2018. Studies presenting data on HTLV prevalence among blood donors in sub‐Saharan Africa were included. A random‐effect meta‐analysis was conducted on all eligible studies.Results: A total of 25 studies were included, representing 74 119 blood donors, of whom over 80% (61 002) were only tested for HTLV‐1. The evidence base was high and moderate in quality. The pooled prevalence of the 17 studies that screened only for HTLV‐1 and the nine studies that screened for HTLV‐1/2 was 0·68 (95% CI: 0·29–1·60) and 1·11 (95% CI: 0·47–2·59) per 100 blood donors, respectively.Conclusion: The prevalence of HTLV‐1 infection among blood donors is relatively low. The current review is intended to inform debates and decisions about best practices to prevent transfusion‐transmitted HTLV in sub‐Saharan Africa. Further work is required to determine the risk of infections by transfusion and the cost‐effectiveness of any new measures such as routine screening.
- 1 January 2018
- Vol. 16 (2) , 145-153
Platelet-, leucocyte- and red cell-derived microparticles in stored whole blood, with and without leucofiltration, with and without ionising radiation
Background. Storage lesion, including microparticle formation, has been partially characterised in whole blood, but not in all combinations of pre-storage leucofiltration and/or irradiation. Materials and methods. Single-donor whole blood products were processed into four subunits: with and without leucofiltration, with and without X-irradiation (25 Gy). Platelet-, leucocyte-, and erythrocyte-derived microparticles and free haemoglobin were measured periodically throughout 42 days of storage. Results. Pre-storage leucofiltration substantially reduced platelet-and leucocyte-derived microparticle counts throughout storage. Irradiation, in contrast, had no significant effect on microparticle counts. A gate for all microparticles showed a substantial time-dependent increase in unfiltered whole blood. A time-dependent increase in free haemoglobin was greatest in unfiltered, irradiated whole blood. Discussion. This study indicates that leucofiltration can prevent the formation of leucocyte-and platelet-derived microparticles, and might reduce haemolysis in irradiated whole blood, either by removing factors that provoke haemolysis, or by selective retention of senescent or effete red cells most prone to haemolysis.
- 1 January 2018
- Vol. 16 (2) , 145-153
Platelet-, leucocyte- and red cell-derived microparticles in stored whole blood, with and without leucofiltration, with and without ionising radiation
Background. Storage lesion, including microparticle formation, has been partially characterised in whole blood, but not in all combinations of pre-storage leucofiltration and/or irradiation. Materials and methods. Single-donor whole blood products were processed into four subunits: with and without leucofiltration, with and without X-irradiation (25 Gy). Platelet-, leucocyte-, and erythrocyte-derived microparticles and free haemoglobin were measured periodically throughout 42 days of storage. Results. Pre-storage leucofiltration substantially reduced platelet-and leucocyte-derived microparticle counts throughout storage. Irradiation, in contrast, had no significant effect on microparticle counts. A gate for all microparticles showed a substantial time-dependent increase in unfiltered whole blood. A time-dependent increase in free haemoglobin was greatest in unfiltered, irradiated whole blood. Discussion. This study indicates that leucofiltration can prevent the formation of leucocyte-and platelet-derived microparticles, and might reduce haemolysis in irradiated whole blood, either by removing factors that provoke haemolysis, or by selective retention of senescent or effete red cells most prone to haemolysis.
- 1 April 2016
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 54 (2) , 296-302
Red blood cell alloimmunization in transfused patients in sub-Saharan Africa: A systematic review and meta-analysis
- 1 April 2016
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 54 (2) , 296-302
Red blood cell alloimmunization in transfused patients in sub-Saharan Africa: A systematic review and meta-analysis
- 29 February 2016
- Published by Wiley in ISBT Science Series
- Vol. 11 (1) , 62-69
A systematic review of red blood cell alloimmunization in pregnant women in Africa: time to do better
- 29 February 2016
- Published by Wiley in ISBT Science Series
- Vol. 11 (1) , 62-69
A systematic review of red blood cell alloimmunization in pregnant women in Africa: time to do better